Back to search
FDAFDA · Food and drugs·Recall number D-0348-2023

Warfarin Sodium Tablets, USP 1 mg, 100-count bottle, Rx Only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC# 57237-119-01

Published March 1, 2023 · Recall initiated: February 15, 2023

Summary

FDA records drug Class II recall D-0348-2023, published March 1, 2023 and initiated February 15, 2023. Recalling firm: RISING PHARMACEUTICALS; Status: Terminated; Reported quantity: 12,216 bottles (100 count each); Lot: Batch #: NB101596, Exp. 04/30/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RISING PHARMACEUTICALS
Distributor
Product was distributed to 16 distributors and 8 wholesalers who may have further distributed the product nationwide.
Lot
Batch #: NB101596, Exp. 04/30/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Warfarin Sodium Tablets, USP 1 mg, 100-count bottle, Rx Only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC# 57237-119-01 recalled?

Yes. FDA published recall D-0348-2023 on March 1, 2023. Reported hazard: Failed Impurities/Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter